FDA granted Breakthrough Therapy Designation Boehringer Ingelheims BI 1015550 - a oral, phosphodiesterase 4B inhibitor (antifibrotic & anti-inflammatory), now in phase II trials for idiopathic pulmonary fibrosis https://t.co/SMXEweSVAR